204 related articles for article (PubMed ID: 34212175)
1. Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network.
Wang Z; Zhang S
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212175
[TBL] [Abstract][Full Text] [Related]
2. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.
Xiao H; Wang B; Xiong HX; Guan JF; Wang J; Tan T; Lin K; Zou SB; Hu ZG; Wang K
J Cell Physiol; 2021 Apr; 236(4):2572-2591. PubMed ID: 32853412
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma.
Lin YR; Yang WJ; Yang GW
Aging (Albany NY); 2021 May; 13(9):12929-12954. PubMed ID: 33952716
[TBL] [Abstract][Full Text] [Related]
4. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
5. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis reveals novel driver genes and molecular subclasses of hepatocellular carcinoma.
Yang L; Zhang Z; Sun Y; Pang S; Yao Q; Lin P; Cheng J; Li J; Ding G; Hui L; Li Y; Li H
Aging (Albany NY); 2020 Nov; 12(23):23849-23871. PubMed ID: 33221766
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
Shimada S; Mogushi K; Akiyama Y; Furuyama T; Watanabe S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Tanabe M; Wands JR; Tanaka S
EBioMedicine; 2019 Feb; 40():457-470. PubMed ID: 30598371
[TBL] [Abstract][Full Text] [Related]
8. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
10. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
[TBL] [Abstract][Full Text] [Related]
11. TCGA and ESTIMATE data mining to identify potential prognostic biomarkers in HCC patients.
He G; Fu S; Li Y; Li T; Mei P; Feng L; Cai L; Cheng Y; Zhou C; Tang Y; Huang W; Liu H; Cen B; Pan M; Gao Y
Aging (Albany NY); 2020 Nov; 12(21):21544-21558. PubMed ID: 33177245
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
Zhao J; Liu Z; Yang K; Shen S; Peng J
Front Immunol; 2024; 15():1333923. PubMed ID: 38736884
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
14. Potential biomarkers for the prognosis and treatment of HCC immunotherapy.
Li H; He Q; Zhou GM; Wang WJ; Shi PP; Wang ZH
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):2027-2046. PubMed ID: 36930502
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a hub gene prognostic index for hepatocellular carcinoma.
Shi Q; Meng Z; Tian XX; Wang YF; Wang WH
Future Oncol; 2021 Jun; 17(17):2193-2208. PubMed ID: 33620260
[TBL] [Abstract][Full Text] [Related]
16. Identification of Therapeutic Targets and Prognostic Biomarkers among Genes from the Mediator Complex Family in the Hepatocellular Carcinoma Tumour-Immune Microenvironment.
Tan W; Peng S; Li Z; Zhang R; Xiao Y; Chen X; Zhu J; Li B; Lv X
Comput Math Methods Med; 2022; 2022():2021613. PubMed ID: 35069777
[TBL] [Abstract][Full Text] [Related]
17. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma.
Wang N; Zhou X; Tang F; Wang X; Zhu X
Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895
[TBL] [Abstract][Full Text] [Related]
18. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
19. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
20. Potential targets and molecular mechanism of miR-331-3p in hepatocellular carcinoma identified by weighted gene coexpression network analysis.
Chi Q; Geng X; Xu K; Wang C; Zhao H
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32537629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
